跳至主要内容
临床试验/ISRCTN10903557
ISRCTN10903557进行中(未招募)未知

Evaluation of the clinical benefits resulting from the application of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel in diagnostics and treatment of bloodstream infections among hospitalized patients

bioMérieux SSC Europe Sp. z o. o.0 个研究点目标入组 150 人开始时间: 2023年1月11日最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Positive blood culture will be eligible for the study
  • 2. Two sets of blood (2x aerobic, 2x anaerobic)
  • 3. Age >18 years
  • 4. Informed consent form to participate in the study

排除标准

  • 1. Age under 18 years
  • 2. Refusal to participate in the study
  • 3. Positive blood culture for the 72 hours follow-up (ex. for Staphylococcus aureus bacteriemia).
  • 4. Patients with blood PCR tests ordered outside the established research protocol and the established randomization. (PCR test ordered by the attending physician due to the patient's severe condition). * in our hospital, the doctor can order a PCR test from blood on his own in the case of a patient in a life-threatening condition, in shock, or for other reasons. Such patients will not be eligible for our study. They may constitute an interesting group of patients in the future, which can be compared with group A planned by our team, where, in addition to the blood PCR test, consultations will be provided on the correct treatment with the appropriate selection of ATB as well as the dosage and duration of treatment.

研究者

发起方
bioMérieux SSC Europe Sp. z o. o.

相似试验